Journal article
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial
K Allott, HP Yuen, L Baldwin, B O’Donoghue, A Fornito, S Chopra, B Nelson, J Graham, MJ Kerr, TM Proffitt, A Ratheesh, M Alvarez-Jimenez, S Harrigan, E Brown, AD Thompson, C Pantelis, M Berk, PD McGorry, SM Francey, SJ Wood
Translational Psychiatry | SPRINGERNATURE | Published : 2023
Abstract
The drivers of cognitive change following first-episode psychosis remain poorly understood. Evidence regarding the role of antipsychotic medication is primarily based on naturalistic studies or clinical trials without a placebo arm, making it difficult to disentangle illness from medication effects. A secondary analysis of a randomised, triple-blind, placebo-controlled trial, where antipsychotic-naive patients with first-episode psychotic disorder were allocated to receive risperidone/paliperidone or matched placebo plus intensive psychosocial therapy for 6 months was conducted. A healthy control group was also recruited. A cognitive battery was administered at baseline and 6 months. Intenti..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The study was supported by Janssen-Cilag, Australia and a Project Grant from the National Health and Medical Research Council, Australia (1064704). Janssen-Cilag partially supported the early years of this study with an unrestricted investigator-initiated grant and provided risperidone, paliperidone and matched placebo for the first 30 participants. The study was then funded by an Australian National Health and Medical Research Project grant (1064704). The funders had no role in study design, data collection, data analysis, data interpretation, writing, approval, or submission of this manuscript.